According to Zacks, “Cutera Inc designs, develops, manufactures and markets the CoolGlide family of products for use in laser and other light-based aesthetic applications. The original CoolGlide CV provides permanent hair reduction on all skin types. The second generation CoolGlide Excel incorporated features that added the capability to treat a variety of vascular lesions, which include facial telangiectasia, spider and reticular leg veins. The CoolGlide Vantage added non-ablative skin therapy to the range of applications offered by the system. “
A number of other research analysts have also weighed in on CUTR. BidaskClub raised shares of Cutera from a hold rating to a buy rating in a research note on Saturday, May 4th. ValuEngine lowered shares of Cutera from a hold rating to a sell rating in a research note on Friday, May 10th. Stephens decreased their price target on shares of Cutera from $40.00 to $25.00 and set an overweight rating on the stock in a research note on Thursday, February 21st. They noted that the move was a valuation call. Maxim Group reaffirmed a hold rating on shares of Cutera in a research note on Monday, February 11th. Finally, TheStreet lowered shares of Cutera from a c rating to a d rating in a research note on Thursday, February 21st. Two analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of Hold and an average target price of $34.67.
Cutera (NASDAQ:CUTR) last issued its quarterly earnings results on Thursday, May 9th. The medical device company reported ($0.59) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.30). The company had revenue of $36.00 million during the quarter, compared to analysts’ expectations of $33.45 million. Cutera had a negative net margin of 22.45% and a negative return on equity of 65.62%. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.02) earnings per share. As a group, equities research analysts forecast that Cutera will post -0.66 earnings per share for the current year.
In related news, Director J Daniel Plants purchased 7,145 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The shares were purchased at an average cost of $16.95 per share, with a total value of $121,107.75. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 1.80% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CUTR. PRW Wealth Management LLC lifted its stake in Cutera by 108.0% in the 1st quarter. PRW Wealth Management LLC now owns 1,951 shares of the medical device company’s stock worth $34,000 after purchasing an additional 1,013 shares in the last quarter. Financial Gravity Companies Inc. purchased a new position in Cutera in the 4th quarter worth approximately $35,000. BNP Paribas Arbitrage SA lifted its stake in Cutera by 56,660.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 2,838 shares of the medical device company’s stock worth $50,000 after purchasing an additional 2,833 shares in the last quarter. Municipal Employees Retirement System of Michigan purchased a new position in Cutera in the 4th quarter worth approximately $65,000. Finally, Metropolitan Life Insurance Co. NY lifted its stake in Cutera by 359.4% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 4,704 shares of the medical device company’s stock worth $80,000 after purchasing an additional 3,680 shares in the last quarter. 91.50% of the stock is currently owned by institutional investors and hedge funds.
Cutera, Inc, a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating.
Recommended Story: How interest rates affect municipal bond prices
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.